{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:15:42Z","timestamp":1774790142484,"version":"3.50.1"},"reference-count":23,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/200.791\/2019"],"award-info":[{"award-number":["E-26\/200.791\/2019"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In Brazil, hepatitis C treatment has been evolving significantly with the licensing of direct-acting antivirals (DAAs). However, viral determinants (amino acid substitutions in hepatitis C virus (HCV) genome and infective genotype) associated with host factors (hepatic condition and prior HCV therapy) might limit the achievement of sustained virologic response (SVR). Here, we described two case reports in which the occurrence of HCV NS5A mutations A30K (subtype 3a) and Y93N (subtype 1a) might have influenced daclatasvir (DCV)\/sofosbuvir (SOF) combined therapy non-response. Despite high response rates for DAA combined therapies in Brazil, these case reports stated the importance of an investigation about how to manage a DAA treatment failure since a combination of factors, especially the occurrence of resistance substitutions, could impact a rescue therapy with new available antivirals in clinical routine.<\/jats:p>","DOI":"10.3390\/v11111004","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T06:33:29Z","timestamp":1572503609000},"page":"1004","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-2658","authenticated-orcid":false,"given":"Vanessa D.","family":"Costa","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio de Hepatites Virais, Instituto Oswaldo Cruz, FIOCRUZ, Avenida Brasil, 4365\u2013Manguinhos, 21040-900 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Hepatologia, Universidade Federal do Rio de Janeiro, Rua Professor Paulo Rodolpho Rocco, 255, Cidade Universit\u00e1ria, 21044-020 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Rotman","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Hepatologia, Universidade Federal do Rio de Janeiro, Rua Professor Paulo Rodolpho Rocco, 255, Cidade Universit\u00e1ria, 21044-020 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Pittella","sequence":"additional","affiliation":[{"name":"Hospital Quinta D\u2019Or. Rua Almirante Baltazar, 435, S\u00e3o Crist\u00f3v\u00e3o, 20941-150 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estev\u00e3o P.","family":"Nunes","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Infectologia Evandro Chagas, INI\/FIOCRUZ, Avenida Brasil, 4365-Manguinhos, 21040-360 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-6309","authenticated-orcid":false,"given":"Barbara V.","family":"Lago","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Hepatites Virais, Instituto Oswaldo Cruz, FIOCRUZ, Avenida Brasil, 4365\u2013Manguinhos, 21040-900 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Lampe","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Hepatites Virais, Instituto Oswaldo Cruz, FIOCRUZ, Avenida Brasil, 4365\u2013Manguinhos, 21040-900 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco C. A.","family":"Mello","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Hepatites Virais, Instituto Oswaldo Cruz, FIOCRUZ, Avenida Brasil, 4365\u2013Manguinhos, 21040-900 Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"ref_1","unstructured":"WHO (2019, April 25). Prevalence of Chronically Infected People with Hepatitis C Virus (HCV) Worldwide. Available online: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","first-page":"886","article-title":"Epidemic history of Hepatitis C virus in Brazil","volume":"10","author":"Lampe","year":"2010","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"ref_3","unstructured":"Minist\u00e9rio da Sa\u00fade, Brasil (2019, April 25). Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es, Available online: http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/protocolo_clinico_diretrizes_hepatite_co_coinfeccoes.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.01874-12","article-title":"In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"Lok","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Malta, F., Gaspareto, K.V., Lisboa-Neto, G., Carrilho, F.J., Mendes-Correa, M.C., and Pinho, J.R.R. (2017). Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2817-7"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Costa, V.D., Brandao-Mello, C.E., Nunes, E.P., Dos Santos Silva, P.G.C., de Souza Rodrigues, L., Lampe, E., and do Amaral Mello, F.C. (2019). Treatment of chronic HCV infection with DAAs in Rio de Janeiro\/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216327"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/jmv.24527","article-title":"Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals","volume":"88","author":"Coppola","year":"2016","journal-title":"J. Med. Virol."},{"key":"ref_12","first-page":"103","article-title":"Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens","volume":"25","author":"Wyles","year":"2017","journal-title":"Top. Antivir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos hepatitis C sequence database","volume":"21","author":"Kuiken","year":"2005","journal-title":"Bioinformatics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/molbev\/msw054","article-title":"MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets","volume":"33","author":"Kumar","year":"2016","journal-title":"Mol. Biol. Evol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-8976-8_1","article-title":"Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus","volume":"1911","author":"Li","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil","volume":"16","author":"Cheinquer","year":"2017","journal-title":"Ann. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3350\/cmh.2016.0107","article-title":"Management of direct antiviral agent failures","volume":"22","author":"Buti","year":"2016","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3851\/IMP3253","article-title":"Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection","volume":"23","author":"Lahser","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/11\/1004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:30:49Z","timestamp":1760189449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/11\/1004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["v11111004"],"URL":"https:\/\/doi.org\/10.3390\/v11111004","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]}}}